<DOC>
	<DOC>NCT01298102</DOC>
	<brief_summary>In 2009, the pandemic influenza A/H1N1 accounted for worldwide recommendations about vaccination. There is no data concerning the immunogenicity nor the security of the adjuvanted-A/H1N1 vaccine in renal disease patients. The aim of this study is to observe the effects of this vaccine on transplanted and hemodialyzed patients.</brief_summary>
	<brief_title>Influenza A/H1N1/2009-adjuvanted Vaccine in Renal Disease Patients</brief_title>
	<detailed_description>The serologic responses to the Pandemrix vaccine will assess the efficacy, with the determination of the seroconversion rate among the patients. The anti-HLA and anti-MICA antibodies will be determined to assess the safety among the renal transplanted patients.</detailed_description>
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1. Adult patients 2. Haemodialyzed patients 3. Renal transplant recipients who have stable renal function for the last 3 months 1. No pneumonia or severe infection during 1 month before vaccination 2. No Ivig (intravenous immunoglobulins) treatment during the last 3 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>kidney</keyword>
	<keyword>transplantation</keyword>
	<keyword>haemodialysis</keyword>
	<keyword>vaccination</keyword>
	<keyword>influenza H1N1 2009</keyword>
</DOC>